Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2018

01-12-2018 | Hepatitis B (J Lim, Section Editor)

Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B

Authors: Clément Lejealle, Laurent Castera

Published in: Current Hepatology Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

Summarizing the available evidence and advantages and disadvantages of the use of non-invasive tests for the management of patients with chronic hepatitis B virus (HBV) infection, including before and during antiviral therapy.

Recent Findings

Staging of liver fibrosis and early detection of compensated cirrhosis are critical in the treatment decisions and surveillance of HBV patients. Non-invasive assessment of liver fibrosis has been one of the major advances in hepatology over the past decade, relying either on the dosage of serum biomarkers or on the measurement of liver stiffness, using either ultrasound- or magnetic resonance-based elastography techniques. The most widely used and validated tests in HBV patients are APRI, FIB-4 (non-patented), and FibroTest-Fibrosure® (patented) for serum biomarkers and transient elastography. Liver stiffness also has prognostic value in the context of cirrhosis.

Summary

Non-invasive tests are now recommended by national and international guidelines as first-line tools for fibrosis assessment.
Literature
1.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.PubMed
2.
Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495–500.PubMed
3.
EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
4.
Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet. 2010;375(9724):1419–20.PubMed
5.
Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1–3.PubMed
6.
•• EASL-ALEH Clinical Practice Guidelines. non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–64 First international guidelines on the use of non-invasive tests.
7.
Dietrich C, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al. EFSUMB Guidelines and Recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med. 2017;38(04):e16–47.PubMed
8.
Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, et al. Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol. 2018.
9.
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357(9262):1069–75.PubMed
10.
Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39(2):222–30.PubMed
11.
Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, et al. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7(4):e35825.PubMedPubMedCentral
12.
Leroy V, Sturm N, Faure P, Trocme C, Marlu A, Hilleret MN, et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61(1):28–34.PubMed
13.
Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One. 2008;3(7):e2573.PubMedPubMedCentral
14.
Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, et al. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest(R)) and elastography (FibroScan(R)). J Hepatol. 2014;61(5):994–1003.PubMed
15.
Castera L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011;33(4):455–65.PubMed
16.
Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42(6):1373–81.PubMed
17.
Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51(10):1867–73.PubMed
18.
Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704–13.PubMed
19.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.PubMed
20.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.PubMed
21.
Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986–92.PubMed
22.
Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016;65(8):1369–76.PubMed
23.
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–302 e4.PubMed
24.
Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100(3):616–23.PubMed
25.
Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005;42(6):1437–45.PubMed
26.
Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Messous D, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol. 2011;11:39.PubMedPubMedCentral
27.
Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302.PubMed
28.
Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver fibrosis in patients with chronic hepatitis B: comparison with serum fibrosis indexes. Radiology. 2017;283(3):873–82.PubMed
29.
Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 2014;109(6):796–809.PubMed
30.
Huang Y, Adams LA, Joseph J, Bulsara MK, Jeffrey GP. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int : Off J Int Assoc Stud Liver. 2017;37(1):121–31.
31.
Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, Chon CY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7(7):e41964.PubMedPubMedCentral
32.
Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14.PubMedPubMedCentral
33.
Xu XY, Kong H, Song RX, Zhai YH, Wu XF, Ai WS, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One. 2014;9(6):e100182.PubMedPubMedCentral
34.
Li Y, Chen Y, Zhao Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis. PLoS One. 2014;9(8):e105728.PubMedPubMedCentral
35.
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2015.
36.
Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.PubMed
37.
Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606–13.PubMed
38.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835–47.PubMed
39.
Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182–91.PubMed
40.
Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968–73.PubMedPubMedCentral
41.
•• Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828–35 Largest study to date regarding the limitations of transient elastography.PubMed
42.
Vuppalanchi R, Siddiqui MS, Van Natta ML, Hallinan E, Brandman D, Kowdley K, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):134–44.PubMed
43.
Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010;59(7):861–6.PubMed
44.
Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int : Off J Int Assoc Study Liver. 2009;29(10):1500–6.
45.
Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, Garcia-Pagan JC, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One. 2013;8(3):e58742.PubMedPubMedCentral
46.
Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int : Off J Int Assoc Study Liver. 2012;32(4):612–21.
47.
Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int: Off J Int Assoc Study Liver. 2012;32(4):622–8.
48.
Xiao H, Shi M, Xie Y, Chi X. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: a systematic review and meta-analysis. PLoS One. 2017;12(11):e0186660.PubMedPubMedCentral
49.
Chon YE, Choi EH, Song KJ, Park JY, Kim do Y, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PloS one. 2012;7(9):e44930.
50.
Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2016;43(4):458–69.PubMed
51.
Hu X, Qiu L, Liu D, Qian L. Acoustic radiation force impulse (ARFI) elastography for noninvasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason. 2017;19(1):23–31.PubMed
52.
Herrmann E, de Lédinghen V, Cassinotto C, Chu WCW, Leung VYF, Ferraioli G, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018;67(1):260–72.PubMed
53.
Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–74.PubMed
54.
•• Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16(1):36–44 First study suggesting that transient elastography cutoffs should be adapted to transaminase levels in patients with chronic hepatitis B.PubMed
55.
Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13(7):402–11.PubMed
56.
Kennedy P, Wagner M, Castera L, Hong CW, Johnson CL, Sirlin CB, et al. Quantitative elastography methods in liver disease: current evidence and future directions. Radiology. 2018;286(3):738–63.PubMedPubMedCentral
57.
Liu Y, Dong CF, Yang G, Liu J, Yao S, Li HY, et al. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. Liver Int: Off J Int Assoc Study Liver. 2015;35(3):816–25.
58.
Zhang D, Chen M, Wang R, Liu Y, Zhang D, Liu L, et al. Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Ultrasound Med Biol. 2015;41(1):7–14.PubMed
59.
Dong CF, Xiao J, Shan LB, Li HY, Xiong YJ, Yang GL, et al. Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B. World J Hepatol. 2016;8(14):616–24.PubMedPubMedCentral
60.
Ozturker C, Karagoz E, Sivrioglu AK, Kara K. Clinical usefulness and performance of acoustic radiation force impulse in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2017;29(6):663–8.PubMed
61.
Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19(2):e212–9.PubMed
62.
Nierhoff J, Chavez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-Rust M. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol. 2013;23(11):3040–53.PubMed
63.
Gao Y, Zheng J, Liang P, Tong M, Wang J, Wu C, et al. Liver fibrosis with two-dimensional US shear-wave elastography in participants with chronic hepatitis B: a prospective multicenter study. Radiology. 2018;172479.
64.
Wang K, Lu X, Zhou H, Gao Y, Zheng J, Tong M, et al. Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut. 2018:gutjnl-2018-316204.
65.
Zeng J, Zheng J, Huang Z, Chen S, Liu J, Wu T, et al. Comparison of 2-D shear wave elastography and transient elastography for assessing liver fibrosis in chronic hepatitis B. Ultrasound Med Biol. 2017;43(8):1563–70.PubMed
66.
Zeng J, Zheng J, Jin JY, Mao YJ, Guo HY, Lu MD, et al. Shear wave elastography for liver fibrosis in chronic hepatitis B: adapting the cut-offs to alanine aminotransferase levels improves accuracy. Eur Radiol. 2018.
67.
Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology. 2013;269(3):910–8.PubMed
68.
Cassinotto C, Lapuyade B, Mouries A, Hiriart JB, Vergniol J, Gaye D, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of supersonic shear imaging with ARFI and FibroScan(R). J Hepatol. 2014;61(3):550–7.PubMed
69.
Gerber L, Kasper D, Fitting D, Knop V, Vermehren A, Sprinzl K, et al. Assessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver disease. Ultrasound Med Biol. 2015;41(9):2350–9.PubMed
70.
Chang W, Lee JM, Yoon JH, Han JK, Choi BI, Yoon JH, et al. Liver fibrosis staging with MR elastography: comparison of diagnostic performance between patients with chronic hepatitis B and those with other etiologic causes. Radiology. 2016;280(1):88–97.PubMed
71.
Lee JE, Lee JM, Lee KB, Yoon JH, Shin CI, Han JK, et al. Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography. Korean J Radiol. 2014;15(2):210–7.PubMedPubMedCentral
72.
Shi Y, Guo Q, Xia F, Dzyubak B, Glaser KJ, Li Q, et al. MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness? Radiology. 2014;273(1):88–98.PubMedPubMedCentral
73.
Shi Y, Xia F, Li QJ, Li JH, Yu B, Li Y, et al. Magnetic resonance elastography for the evaluation of liver fibrosis in chronic hepatitis B and C by using both gradient-recalled echo and spin-echo echo planar imaging: a prospective study. Am J Gastroenterol. 2016;111(6):823–33.PubMed
74.
Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24(1):70–8.PubMed
75.
Wu WP, Chou CT, Chen RC, Lee CW, Lee KW, Wu HK. Non-invasive evaluation of hepatic fibrosis: the diagnostic performance of magnetic resonance elastography in patients with viral hepatitis B or C. PLoS One. 2015;10(10):e0140068.PubMedPubMedCentral
76.
Trembling PM, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, et al. Performance of enhanced liver fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat. 2014;21(6):430–8.PubMed
77.
Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, et al. Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014;39(2):197–208.PubMed
78.
Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol: WJG. 2008;14(40):6154–62.PubMed
79.
Maimone S, Calvaruso V, Pleguezuelo M, Squadrito G, Amaddeo G, Jacobs M, et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J Viral Hepat. 2009;16(11):769–74.PubMed
80.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.PubMed
81.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.PubMed
82.
Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100(9):1970–80.PubMed
83.
Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat. 2009;16(3):203–13.PubMed
84.
Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 2011;16(2):165–72.PubMed
85.
Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat. 2011;18(7):e200–5.PubMed
86.
Lim SG, Cho SW, Lee YC, Jeon SJ, Lee MH, Cho YJ, et al. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. Hepato-Gastroenterology. 2011;58(106):539–45.PubMed
87.
Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773–80.PubMed
88.
Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, et al. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014;9(3):e93160.PubMedPubMedCentral
89.
Liang X, Xie Q, Tan D, Ning Q, Niu J, Bai X, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study. J Viral Hepat. 2018;25(3):296–305.PubMed
90.
Berzigotti A. Non-invasive evaluation of portal hypertension using ultrasound elastography. J Hepatol. 2017;67(2):399–411.PubMed
91.
Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012;56(3):696–703.PubMed
92.
•• de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52 First guidelines incorporating liver stiffness measured using transient elastography for the stratification of patients and management of portal hypertension.PubMed
93.
Marot A, Trepo E, Doerig C, Schoepfer A, Moreno C, Deltenre P. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int : Off J Int Assoc Study Liver. 2017;37(5):707–16.
94.
Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia-Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int: Off J Int Assoc Study Liver. 2017;37(8):1177–83.
95.
Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S, et al. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol. 2016;65(5):899–905.PubMed
96.
Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64(6):2173–84.PubMed
97.
Llop E, Lopez M, de la Revilla J, Fernandez N, Trapero M, Hernandez M, et al. Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease. J Gastroenterol Hepatol. 2017;32(11):1867–72.PubMed
98.
Bae J, Sinn DH, Kang W, Gwak GY, Choi MS, Paik YH, et al. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver Int : Off J Int Assoc Study Liver. 2018;38(8):1442–8.
99.
Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66(6):1980–8.PubMed
100.
Colecchia A, Ravaioli F, Marasco G, Colli A, Dajti E, Di Biase AR, et al. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. J Hepatol. 2018;69(2):308–17.PubMed
101.
Chon YE, Jung ES, Park JY, Kim do Y, Ahn SH, Han KH, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol. 2012;46(6):518–25.PubMed
102.
•• Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park JY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53(3):885–94 First study showing a relationship between liver stiffness and hepatocellular carcinoma in patients with hepatitis B.PubMed
103.
Kim JH, Kim JW, Seo JW, Choe WH, Kwon SY. Noninvasive tests for fibrosis predict 5-year mortality and hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol. 2016;50(10):882–8.PubMed
104.
Kim MN, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61(6):1851–9.PubMed
105.
Feier D, Lupsor Platon M, Stefanescu H, Badea R. Transient elastography for the detection of hepatocellular carcinoma in viral C liver cirrhosis. Is there something else than increased liver stiffness? J Gastrointestin Liver Dis. 2013;22(3):283–9.PubMed
106.
Kim do Y, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, et al. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther. 2013;6:1463–9.PubMed
107.
Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60(2):339–45.PubMed
108.
Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–5.PubMed
109.
Kim SU, Lee JH, Kim do Y, Ahn SH, Jung KS, Choi EH, et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PloS one. 2012;7(5):e36676.PubMedPubMedCentral
110.
de Ledinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B, et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37(10):979–88.PubMed
111.
Park MS, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, et al. Prognostic value of the combined use of transient elastography and FibroTest in patients with chronic hepatitis B. Liver Int: Off J Int Assoc Study Liver. 2015;35(2):455–62.
112.
Wong GL, Chan HL, Yu Z, Wong CK, Leung C, Ho PP, et al. Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(3):582–90.PubMed
113.
Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem. 2006;52(10):1887–96.PubMed
114.
Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2013;11(12):1573–84 e1–2 quiz e88–9.
115.
Gines P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol. 2016;1(3):256–60.PubMed
Metadata
Title
Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B
Authors
Clément Lejealle
Laurent Castera
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0439-1

Other articles of this Issue 4/2018

Current Hepatology Reports 4/2018 Go to the issue

Hepatitis B (J Lim, Section Editor)

Long-term Outcomes in Patients with HBV Treated with Antiviral Agents

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma

Fatty Liver Disease (Z Younossi, Section Editor)

The Clinical and Economic Burden of Nonalcoholic Steatohepatitis

Fatty Liver Disease (Z Younossi, Section Editor)

The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Fatty Liver Disease (Z Younossi, Section Editor)

Pathogenesis of NASH: the Impact of Multiple Pathways

Hepatitis B (J Lim, Section Editor)

Update in the Management of Chronic Hepatitis B in Pregnancy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits